Lion Biotechnologies, Inc. (IOVA) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Lion Biotechnologies, Inc. (NASDAQ:IOVA) from a hold rating to a buy rating in a research note released on Tuesday, July 18th. They currently have $7.00 target price on the biotechnology company’s stock.

According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “

IOVA has been the topic of several other reports. HC Wainwright reiterated a buy rating and set a $16.00 target price on shares of Lion Biotechnologies in a research report on Wednesday, June 7th. Chardan Capital increased their target price on Lion Biotechnologies from $18.00 to $20.00 and gave the stock a buy rating in a research report on Thursday, May 4th. Rodman & Renshaw initiated coverage on Lion Biotechnologies in a research note on Wednesday, May 10th. They set a buy rating and a $13.00 price target for the company. Cowen and Company restated a buy rating on shares of Lion Biotechnologies in a research note on Wednesday, April 19th. Finally, FBR & Co restated a buy rating on shares of Lion Biotechnologies in a research note on Thursday, May 18th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Lion Biotechnologies presently has a consensus rating of Buy and a consensus price target of $13.88.

Shares of Lion Biotechnologies (NASDAQ IOVA) opened at 5.15 on Tuesday. The stock has a 50 day moving average of $6.37 and a 200-day moving average of $6.68. Lion Biotechnologies has a 52 week low of $4.90 and a 52 week high of $9.58. The company’s market capitalization is $322.84 million.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/08/13/lion-biotechnologies-inc-iova-upgraded-to-buy-by-zacks-investment-research-updated-updated-updated.html.

Large investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new stake in Lion Biotechnologies during the second quarter worth about $103,000. Parametric Portfolio Associates LLC bought a new stake in Lion Biotechnologies during the second quarter worth about $125,000. ProShare Advisors LLC bought a new stake in Lion Biotechnologies during the second quarter worth about $270,000. State of Wisconsin Investment Board bought a new stake in Lion Biotechnologies during the second quarter worth about $287,000. Finally, Atlantic Trust Group LLC bought a new stake in Lion Biotechnologies during the second quarter worth about $316,000. Institutional investors and hedge funds own 77.82% of the company’s stock.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Lion Biotechnologies (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply